TY - JOUR
T1 - Roles of Fc domain and exudation in L2 antibody-mediated protection against human papillomavirus
AU - Wang, Joshua W.
AU - Wu, Wai Hong
AU - Huang, Tsui Chin
AU - Wong, Margaret
AU - Kwak, Kihyuck
AU - Ozato, Keiko
AU - Hung, Chien Fu
AU - Roden, Richard B.S.
N1 - Funding Information:
The study was funded by grants from the National Cancer Institute (P50 CA098252 and CA118790) and the V foundation (http://www.jimmyv.org/) to Richard B. S. Roden. Chimera was developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco (supported by NIGMS grant P41-GM103311). Joshua W. Wang is a founder of PathoVax LLC. Richard B. S. Roden is a cofounder of and has an equity ownership interest in Papivax LLC, and he owns Papivax Biotech Inc. stock options and is a member of Papivax Biotech Inc.'s scientific advisory board. Richard B. S. Roden is an inventor of L2-related patents licensed by The Johns Hopkins University to PathoVax LLC and BravoVax. Richard B. S. Roden has received research funding from Sanofi Pasteur, Shantha Biotechnic, and GlaxoSmithKline; has an equity ownership interest in PathoVax LLC; and is a member of PathoVax LLC's scientific advisory board. These arrangements have been reviewed and approved by The Johns Hopkins University in accordance with its conflict-of-interest policies.
Funding Information:
The study was funded by grants from the National Cancer Institute (P50 CA098252 and CA118790) and the V foundation (http://www.jimmyv.org/) to Richard B. S. Roden. Chimera was developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco (supported by NIGMS grant P41-GM103311).
Publisher Copyright:
© 2018 American Society for Microbiology.
PY - 2018/8/1
Y1 - 2018/8/1
N2 - To address how L2-specific antibodies prevent human papillomavirus (HPV) infection of the genital tract, we generated neutralizing monoclonal antibodies (MAbs) WW1, a rat IgG2a that binds L2 residues 17 to 36 (like mouse MAb RG1), and JWW3, a mouse IgG2b derivative of Mab24 specific for L2 residues 58 to 64. By Western blotting, WW1 recognized L2 of 29/34 HPV genotypes tested, compared to only 13/34 for RG1 and 25/34 for JWW3. WW1 IgG and F(ab')2 bound HPV16 pseudovirions similarly; however, whole IgG provided better protection against HPV vaginal challenge. Passive transfer of WW1 IgG was similarly protective in wild-type and neonatal Fc receptor (FcRn)-deficient mice, suggesting that protection by WW1 IgG is not mediated by FcRn-dependent transcytosis. Rather, local epithelial disruption, required for genital infection and induced by either brushing or nonoxynol-9 treatment, released serum IgG in the genital tract, suggesting Fc-independent exudation. Depletion of neutrophils and macrophages reduced protection of mice upon passive transfer of whole WW1 or JWW3 IgGs. Similarly, IgG-mediated protection by L2 MAbs WW1, JWW3, and RG1 was reduced in Fc receptor knockout compared to wild-type mice. However, levels of in vitro neutralization by WW1 IgG were similar in TRIM21 knockout and wild-type cells, indicating that Fc does not contribute to antibody-dependent intracellular neutralization (ADIN). In conclusion, the Fc domain of L2-specific IgGs is not active for ADIN, but it opsonizes bound extracellular pseudovirions for phagocytes in protecting mice from intravaginal HPV challenge. Systemically administered neutralizing IgG can access the site of infection in an abrasion via exudation without the need for FcRn-mediated transcytosis.
AB - To address how L2-specific antibodies prevent human papillomavirus (HPV) infection of the genital tract, we generated neutralizing monoclonal antibodies (MAbs) WW1, a rat IgG2a that binds L2 residues 17 to 36 (like mouse MAb RG1), and JWW3, a mouse IgG2b derivative of Mab24 specific for L2 residues 58 to 64. By Western blotting, WW1 recognized L2 of 29/34 HPV genotypes tested, compared to only 13/34 for RG1 and 25/34 for JWW3. WW1 IgG and F(ab')2 bound HPV16 pseudovirions similarly; however, whole IgG provided better protection against HPV vaginal challenge. Passive transfer of WW1 IgG was similarly protective in wild-type and neonatal Fc receptor (FcRn)-deficient mice, suggesting that protection by WW1 IgG is not mediated by FcRn-dependent transcytosis. Rather, local epithelial disruption, required for genital infection and induced by either brushing or nonoxynol-9 treatment, released serum IgG in the genital tract, suggesting Fc-independent exudation. Depletion of neutrophils and macrophages reduced protection of mice upon passive transfer of whole WW1 or JWW3 IgGs. Similarly, IgG-mediated protection by L2 MAbs WW1, JWW3, and RG1 was reduced in Fc receptor knockout compared to wild-type mice. However, levels of in vitro neutralization by WW1 IgG were similar in TRIM21 knockout and wild-type cells, indicating that Fc does not contribute to antibody-dependent intracellular neutralization (ADIN). In conclusion, the Fc domain of L2-specific IgGs is not active for ADIN, but it opsonizes bound extracellular pseudovirions for phagocytes in protecting mice from intravaginal HPV challenge. Systemically administered neutralizing IgG can access the site of infection in an abrasion via exudation without the need for FcRn-mediated transcytosis.
KW - Antibody-mediated protection
KW - Cross-protection
KW - Fc
KW - FcRn
KW - Human papillomavirus
KW - Humoral immunity
KW - L2 protein
KW - Monoclonal antibody
KW - Neutralizing antibodies
KW - TRIM21
UR - http://www.scopus.com/inward/record.url?scp=85050077040&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050077040&partnerID=8YFLogxK
U2 - 10.1128/JVI.00572-18
DO - 10.1128/JVI.00572-18
M3 - Article
C2 - 29743371
AN - SCOPUS:85050077040
SN - 0022-538X
VL - 92
JO - Journal of Virology
JF - Journal of Virology
IS - 15
M1 - e00572-18
ER -